Altitude Life Science Ventures (ALSV)

Type

Venture Capital

Status

Active

Location

Durango, United States

Total investments

43

Average round size

90M

Portfolio companies

25

Rounds per year

2.39

Follow on index

0.40

Exits

9

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareGeneticsMedicalLife SciencePharmaceuticalTherapeuticsChemicalBiopharmaNanotechnology

Summary

The main office of represented VC is situated in the Durango. The venture was found in North America in United States.

The usual cause for the fund is to invest in rounds with 7-8 partakers. Despite the Altitude Life Science Ventures, startups are often financed by Venrock, OUP (Osage University Partners), Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Venrock, The Column Group, Versant Ventures. In the next rounds fund is usually obtained by The Column Group, Venrock, Third Rock Ventures.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Life Science, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Receptos, Vir Biotechnology, Kythera Biopharmaceuticals. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.

The current fund was established by Dave Maki, David Maki, Steve Johnson, Steve Johnson. The overall number of key employees were 2.

The higher amount of exits for fund were in 2018. The fund is constantly included in 2-6 investment rounds annually. Comparing to the other companies, this Altitude Life Science Ventures performs on 7 percentage points less the average number of lead investments. The usual things for fund are deals in the range of 50 - 100 millions dollars. The top activity for fund was in 2019. The real fund results show that this VC is 13 percentage points less often commits exit comparing to other companies.

Show more

Investor highlights

Industry focus
Biotech/Life Sciences
Stage focus
Series ASeries B

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
43
Lead investments
0
Exits
9
Rounds per year
2.39
Follow on index
0.40
Investments by industry
  • Biotechnology (40)
  • Health Care (16)
  • Therapeutics (13)
  • Medical (12)
  • Biopharma (9)
  • Show 12 more
Investments by region
  • United States (40)
Peak activity year
2021
Number of Unicorns
3
Number of Decacorns
3

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
9
Avg. valuation at time of investment
208M
Group Appearance index
1.00
Avg. company exit year
12
Avg. multiplicator
3.49
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Encoded Therapeutics 26 Jun 2019 Biotechnology, Health Care, Genetics, Therapeutics Late Stage Venture 104M United States, California, South San Francisco
Vilya 04 Jun 2024 Biotechnology, Health Diagnostics, Medical, Life Science Early Stage Venture 21M United States, Washington, Seattle

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.